BIOCON · Biocon Limited · Documents

370.95 INR +2.90 (+0.79%) At close · Nov 12

Market Cap

604.54B INR

1.63B

Volume · Nov 12 2.96M Avg daily vol (3M) 3.09M

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 4, 2026

2026

Nov 4

Earnings call

Stronger second half expected with $400 million Brazil contract

Biocon Limited reported 2% year-on-year operating revenue growth in Q2FY27 and expects H2 to be stronger than H1. Its 10-year, $400 million Brazilian Pertuzumab contract is scheduled to begin supplies in Q4FY27.

6 source passages

Ladies and gentlemen, good day, and welcome to Biocon Limited Q2 FY27 Earnings Conference Call. In Q2FY27, the group delivered a 2% year-on-year growth in operating revenues. We expect H2 to be stronger than H1, supported by improving biosimilars momentum, as I talked about earlier, continued profitability improvement in generics, which we have demonstrated for the last couple of quarters and a progressive recovery at Syngene, which is demonstrated in Q2 over Q1. Biocon Biologics was recently awarded a landmark 10-year contract with a total contract value of $400 million under the Brazilian government's Productive Development Partnership, or the PDP program, as it is called, in partnership with Bahiafarma and Bionovis, as Kiran talked about earlier. Supplies to this program are scheduled to begin in Q4FY27. We are excited to bring biosimilar Pertuzumab to patients in Brazil. Open the document at this passage

Aug 6

Earnings call

Q1 2027 earnings call AI summary on its way

May 8

Earnings call

Q4 2026 earnings call AI summary on its way

Showing 1–3 of 3 documents